# Cannabichromene Safety in Rheumatoid Arthritis

> **NCT07087938** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Crystal Lederhos Smith** · enrollment: 25 (estimated)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Cannabichromene

## Key facts

- **NCT ID:** NCT07087938
- **Lead sponsor:** Crystal Lederhos Smith
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2028-07-15
- **Primary completion:** 2030-05-31
- **Final completion:** 2030-05-31
- **Target enrollment:** 25 (ESTIMATED)
- **Why stopped:** This study was put on clinical hold with the FDA prior to beginning enrollment due to insufficient preclinical evidence.
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07087938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07087938, "Cannabichromene Safety in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07087938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*